Post-Traumatic Stress Disorder (PTSD) and Seroquel

Cambridge Health Alliance34 enrolled

Overview

This 8 weeks study will investigate therapeutic responses to Seroquel pharmacotherapy in PTSD.

An initial telephone interview will be conducted to determine if potential subjects meet the basic study requirements. If no obvious counterindications are present, subjects will be scheduled for a screening visit. After briefing the subjects on the reasons for the research, they will be given an opportunity to read the Informed Consent Form, approved by the Cambridge Health Alliance Institutional ReviewBoard, and to ask questions prior to signing it. Subjects will be given a copy of the signed Consent Form. Each subject will complete a standardized interview schedule designed to obtain personal and background data along with psychodiagnostic and psychometric evaluations. An open-label treatment will be utilized for all patients. Seroquel tablets will be flexibly dosed and begun at a target dose of 25 mg per day and taken over an 8 week period.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Post-Traumatic Stress Disorder

Interventions

SeroquelDRUG

This study will investigate therapeutic responses to Seroquel pharmacotherapy in PTSD

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Provision of written informed consent * Fluency in English * A diagnosis of PTSD * No pregnancy * Right-handedness Exclusion Criteria: * Pregnancy or lactation * Any cognitive impairment that precludes informed consent * Known intolerance or lack of response to Seroquel * Previous enrollment or randomization of treatment in the present study * Participation in another drug trial within 4 weeks prior enrollment into this study * Patients with Diabetes Mellitus * History of allergic reaction or hypersensitivity to Seroquel * Contraindications to magnetic resonance imaging * Treatment with an effective medication for PTSD

Locations (1)

Central Street Health Center

Somerville, Massachusetts, United States

Outcomes

Primary Outcomes

Change From Baseline in PTSD Symptomatology at the Week 8 Timepoint.

We will compare patients' symptomatology at baseline vs. at 8 week timepoint Specify Full Scale Name and Construct (i.e., indicate what the scale measures if not clear from name): Clinician-Administered PTSD Scale (CAPS) Include all scale ranges (i.e., minimum and maximum scores) required to interpret any values in the data table: 0-136 For each scale range provided, specify which values are considered to be a better or worse outcome: 0-best, 136 worst If subscales are combined to compute a total score, consider indicating how subscales are combined (summed, averaged, etc.): summed

Time frame: 8 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.